Replies to post #792198 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Gro,

It sounds like you can hear the “Thundering Herd” advancing into our midst!



Northwest Biotherapeutics (Pittsburgh, UCLA, Roswell Park)

ImmunoRestoration (Moffitt)

Mill Creek Life Sciences (Mayo Clinic)

Diakonos Oncology

NWBO appears to be emerging as the leader, with academic/industry relationships, a broad IP portfolio, manufacturing capacity, & multiple platforms…

But the key point is that it’s not a zero-sum game. Success in any one clinical trial, institution, or company validates the field of cell-based technology, reinforces proof of concept, & advances the science—opening doors to broader adoption, broader market demand, regulatory confidence, & investor interest.

Beyond those examples mentioned above, more companies are emerging— & others soon will. Each will make a contribution to the field & may create opportunities for collaboration, partnerships, or acquisitions.

Kalinski Heads to Pitt



Recent Conference

Pennies in Action

Moffitt

[Slave1]

Provenge makes weak, single-antigen cells with low IL-12, so immunity fades quickly. Next

[seekinganswers]

As of October 2025, approximately 120 dendritic cell (DC) clinical trials are ongoing worldwide, based on data from ClinicalTrials.gov and other sources like the European Union Clinical Trials Register (EU CTR). This number reflects trials in "Recruiting" or "Active, not recruiting" statuses. Below is an updated and concise breakdown tailored to your request for 2025:Primary Focus: ~90% are oncology-focused (e.g., melanoma, glioblastoma, lung, prostate, breast cancers), with ~10% targeting non-cancer conditions like multiple sclerosis or infectious diseases (e.g., COVID-19 vaccines).
Breakdown:Cancer Trials: ~110 trials (e.g., 15 for glioma, 8 for lung cancer, 5–10 each for melanoma/prostate, NATASHA trial for HER2+ breast cancer recruiting as of July 2025).
Non-Cancer Trials: ~10 trials (e.g., 5 for multiple sclerosis, with 2 recruiting).
Phases: ~70% Phase I/II, ~10% Phase III/IV (e.g., ImmunoTACE for HCC, with follow-ups ongoing post-2025 results).
Regions: U.S. (50), Europe (40), Asia/Others (~30).

[Slave1]

The M7 dendritic-cell maturation protocol used by the Mayo Clinic employs the same type-1 polarization logic originally established by Dr. Pawel Kalinski and subsequently in-licensed by Northwest Biotherapeutics